Most pharma companies post higher annual profits
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
February 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, FEBRUARY 06, 2023
Most pharma companies post higher annual profits

Economy

Rafiqul Islam
09 November, 2021, 10:30 pm
Last modified: 10 November, 2021, 11:00 am

Related News

  • How pharmas performed against high headwinds
  • Semiconductor, pharma should get more attention
  • Pharma industry needs to prepare for headwinds
  • US move to negotiate drug prices a rare defeat for Big Pharma
  • Pharma companies: A safe haven for investors in this bear market

Most pharma companies post higher annual profits

Pandemic helps drugs and hygiene products manufacturers post a sharp surge in sales

Rafiqul Islam
09 November, 2021, 10:30 pm
Last modified: 10 November, 2021, 11:00 am
Drugmakers find silver lining in pandemic
Infograph: TBS

Most listed pharmaceutical and chemical companies have registered a higher profit in fiscal 2020-2021 compared to the previous year riding on a jump in sales during the Covid-19 pandemic.

Eight of the companies will pay a higher dividend than the previous fiscal year, four will disburse the same amount as it did a year ago while three firms, which reported a decline in profit, will reduce their dividend.

Drugs and hygiene products manufactured by pharmaceuticals and chemicals companies saw a sharp surge in sales during the pandemic.

It helped the pharmaceutical companies in the country to post good growth in terms of both revenue and profit compared to the previous fiscal year, according to industry insiders.

Until 8 November, 20 out of 31 including two listed foreign multinational companies in the pharmaceuticals and chemicals sector have published their annual financials for the 2020-2021 fiscal year.

Eleven of the companies have reported an increase in profit, and nine witnessed a profit decline compared to the previous fiscal year, according to an analysis by The Business Standard.

The rest of the companies from this sector are yet to publish their annual financials and declare a dividend for shareholders.

As per available data, three companies have incurred losses. Among them, two had incurred losses in the previous fiscal year too.

Two other companies have returned to profit last fiscal year, they incurred losses in the previous fiscal.

According to industry insiders, the annual growth of the pharmaceutical industry may go as high as 15-16% this decade, which has been 12.1% for the last five years.

The pandemic helped the industry achieve a staggering 18.56% growth in the 2020-21 fiscal year.

Beximco Pharmaceuticals, Square Pharmaceuticals, and Renata are in the club of more than Tk500 crore profit among the dozens of companies listed on the country's stock market.

In the pandemic, these companies reported a sharp rise in profits in the outgoing fiscal year. 

Beximco Pharmaceuticals' profit grew by 46% in FY21. Its consolidated earnings per share (EPS) stood at Tk11.49, which was Tk7.88 in the previous fiscal year.

Officials at the company said profit increased from its organic growth of business and part of this is attributable to the income from vaccine distribution and increased cash incentive from exports.

Square Pharmaceuticals – the industry leader – has posted a 19% increase in profit and its EPS rose to Tk17.99 from Tk15.07 in the previous year.

It said in an annual declaration, the growth is in its core business. The sales of pharmaceutical products have positively affected the EPS. 

Renata, the descendent of Pfizer Bangladesh, posted a 26% increase in profit. Its EPS rose to Tk51.94 from Tk41.14 in the previous year.

Orion Pharma registered a 41% increase in profit in FY21. Its consolidated EPS rose to Tk4.1 from Tk2.84 in the previous fiscal year. 

The IBN Sina Pharmaceutical's profit rose by 26%. Its EPS rose to Tk15.66 from Tk12.56 in the previous fiscal year.

Md Kabir Hossain, company secretary at IBN Sina, recently told The Business Standard, "Amid the pandemic, our revenue from drugs sales increased significantly. As a result, profit increased compared to the previous year."

ACI Formulations – an agrochemical manufacturer and supplier – has witnessed a 130% jump in profit compared to the previous year. Its EPS stood at Tk4.74, which was Tk2.06 in the previous year.

Advanced Chemical Industries (ACI) Limited – one of the country's largest conglomerates and manufacturers of pharmaceutical products – has returned to profit in the last fiscal year.

This fiscal year, ACI's EPS reached Tk5.5. In the previous year, its loss per share was Tk16.78.

Also, ACME Laboratories, Global Heavy Chemicals, Kohinoor Chemicals Company (Bangladesh), and Silva Pharmaceuticals have posted higher profits compared to the previous fiscal year.

On the other hand, Beximco Synthetics, Central Pharmaceuticals, and Far Chemical Industries have incurred losses. 

In which, Beximco Synthetics and Central Pharmaceuticals have continued incurring losses like the previous year.

Hence, they will not pay any dividends to their shareholders.

Far Chemicals Industries is a newcomer among the loss-making firms in the pharma sector, and despite the losses, the company will pay a 1% cash dividend.

Top News

Pharma / pharmaceutical companies / higher annual profits / Annual profit

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A man walks past by a collapsed building after an earthquake in Malatya, Turkey February 6, 2023. Depo Photos via REUTERS
    Over 600 dead, many trapped under rubble as 7.9 magnitude quake rocks Turkey and Syria
  • LC issues lead to severe shortage of surgical equipment
    LC issues lead to severe shortage of surgical equipment
  • A stinking open garbage bin in the Gazipur City Corporation area causes problems to commuters. Lack of proper measures, including designated spots, manpower and equipment for dumping garbage, has made the city corporation area an open trash bin. Photo: TBS
    Waste collection fees likely to go up for Dhaka north residents

MOST VIEWED

  • The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
    IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms
  • Will reform pledges to IMF work this time?
    Will reform pledges to IMF work this time?
  • Infographic: TBS
    Bangladesh in better position than Sri Lanka, Pakistan to navigate forex crisis: UCB Asset Management
  • Despite downturn 3 dozen listed firms plan Tk7,500cr investment
    Despite downturn 3 dozen listed firms plan Tk7,500cr investment
  • International Monetary Fund logo : AP via UNB
    IMF sets time-bound reform agenda as it releases first tranche of loan
  • NBFIs can no longer borrow from call money market: Cenbank
    NBFIs can no longer borrow from call money market: Cenbank

Related News

  • How pharmas performed against high headwinds
  • Semiconductor, pharma should get more attention
  • Pharma industry needs to prepare for headwinds
  • US move to negotiate drug prices a rare defeat for Big Pharma
  • Pharma companies: A safe haven for investors in this bear market

Features

Photo: Collected

Get your partner a lovely present this Valentine's Day

4h | Brands
Pottery Wheel Craft Kit: A creative outlet for little hands

Pottery Wheel Craft Kit: A creative outlet for little hands

3h | Brands
Say it with Colours

Say it with Colours

1d | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

1d | Panorama

More Videos from TBS

Stage plays are going on in the digital age

Stage plays are going on in the digital age

3h | TBS Stories
Why does all the versatile roles go to Jisan?

Why does all the versatile roles go to Jisan?

3h | TBS Entertainment
ICB to withdraw Padma Bank Investment as return

ICB to withdraw Padma Bank Investment as return

20h | TBS Insight
Kiara Advani & Sidharth Malhotra's Wedding Update

Kiara Advani & Sidharth Malhotra's Wedding Update

20h | TBS Entertainment

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

6
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]